GSK shares fall as narrow approval of blood cancer drug limits US relaunch – Reuters

Written by

admin

in

  1. GSK shares fall as narrow approval of blood cancer drug limits US relaunch  Reuters
  2. FDA delivers split decision on GSK’s blood cancer drug Blenrep, approving its use in some cases  statnews.com
  3. GSK’s Blenrep’s back in US, but with a narrower label  pharmaphorum
  4. Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD  AJMC
  5. Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma  Business Wire

Continue Reading

More posts